Persistent genital arousal disorder: The uninvited guest (Part 1)

By Brooke M. Faught, MSN, WHNP-BC, IF

Persistent genital arousal disorder (PGAD) is a perplexing and elusive health condition of unknown prevalence. Until recently, little was known about its etiology or amenability to treatment. However, recent advances in sexual medicine research provide a better understanding of PGAD, enabling healthcare providers’ ability to properly diagnose and manage it. In part 1 of this two-part series, diagnosis and management of PGAD are discussed; in part 2, the focus is on the patient experience of PGAD.

Prevalence and etiology

Little is known about PGAD prevalence. Most research on PGAD is in the form of case studies or surveys of limited populations. PGAD is likely under-reported because of patient embarrassment and fear of being labeled as hypersexual. A survey of a sexual health practice in the United Kingdom identified a PGAD prevalence of approximately 1% with all the diagnostic characteristics of the condition, although 33% of participants reported at least one identifying characteristic of PGAD. PGAD appears to affect women of all ages. A recent survey of more than 100 women with PGAD indicated an age range of 18-79 years (mean age, 47 years).

No consensus exists regarding the etiology of PGAD, although it is thought that symptoms may arise as a result of dysregulation at central and peripheral levels. In addition, psychological conditions and external factors such as...
as diet and pharmacologic agents may elicit symptoms of persistent arousal. Antidepressant use is cited as a trigger in 20% of women with PGAD. Vascular anomalies of the pelvis and compression of the pudendal nerve, as with Tarlov cysts, may play a role in some cases.

**Diagnosis**

Women vary in terms of the presentation and experience of PGAD (Box). Because women may hesitate to disclose information about PGAD, HCPs should consider asking those presenting for annual checkups about whether they experience any genital pain, discomfort, persistent arousal, numbness, tingling, or throbbing. If PGAD is suspected, HCPs should review the patient’s health history, with a focus on potential co-morbidities and past/current medication use, supplement use, and illicit drug use. Diet and exercise are important factors when assessing for PGAD. In addition, women should be asked about past and current sexual practices and partner(s), as well as a possible history of sexual abuse or trauma.

A comprehensive vulvovaginal and pelvic examination, including a neurologic and musculoskeletal assessment, can identify or exclude overt structural defects. In some cases, laboratory testing (e.g., thyroid panel, prolactin level, testosterone panel) and imaging studies (e.g., pelvic ultrasonography, magnetic resonance imaging) may provide useful diagnostic information.

Women with PGAD should be screened for symptoms of restless leg syndrome (RLS) and overactive bladder (OAB). If symptoms of RLS and/or OAB co-exist with those of PGAD, a diagnosis of restless genital syndrome should be considered.

---

**Box. Presentation and experience of persistent genital arousal disorder**

**Definition**
Feelings of genital arousal or impending orgasm not associated with sexual fantasies, thoughts, or interest.

**Characteristics**
- Persistent or recurrent
- Unwanted or intrusive
- Distressing
- ≥6 months’ duration of symptoms

**Associated with (one or more):**
- Limited or lack of symptom resolution or worsening of symptoms with genital stimulation or orgasm
- Aggravation of symptoms by specific circumstances
- Mood changes such as despair, depression, emotional lability, catastrophizing, and/or suicidality
- Inconsistent evidence of genital arousal with presentation of symptoms

Adapted from Parish et al, 2016.

---

**Treatment**

No medications are currently indicated specifically for the treatment of PGAD. All pharmacologic interventions for PGAD discussed in this article are investigational. Of note, HCPs should address potentially reversible causes of PGAD *before* pursuing further intervention. As with many complex and poorly understood health conditions, the treatment for PGAD necessitates an interdisciplinary approach, with consideration of all potential biopsychosocial causes. Further supporting the multifactorial causation of PGAD is the fact that clitoridectomy does not appear to benefit patient outcomes.

Dysregulation of sensory excitation remains the focus of pharmacologic intervention for PGAD. Off-label use of medications such as selective serotonin reuptake inhibitors, varenicline, zolpidem, and tramadol appears to reduce PGAD symptoms in some cases, although further research is needed. Of interest, withdrawal from the aforementioned medications has been implicated in the onset of PGAD. Surgical correction of Tarlov cysts may effectively treat PGAD, whereas periclitoral injections of botulinum toxin do not appear to improve symptoms long term. Electroconvulsive therapy may ameliorate PGAD symptoms in patients with co-morbid bipolar disorder.
**Recommendations**

Persistent genital arousal disorder is a legitimate health condition that warrants increased HCP awareness.⁸ Although PGAD is often represented in a comedic light, it is no laughing matter to women who carry the daily burden of the embarrassing and debilitating symptoms that accompany it. Women with PGAD report insensitive comments from their HCPs such as “You should be a porn star” or “Your symptoms are every husband’s dream.”⁹ Comments from a trusted HCP that embarrass, insult, or ridicule an already vulnerable woman can have devastating consequences. Compared with the general population, patients with PGAD have a two-fold increase in suicidal ideation.¹⁰ Care of patients with PGAD begins by providing a safe and nonjudgmental atmosphere in which to facilitate an open and honest discussion. If PGAD is suspected, HCPs can consider referral to a sexual medicine provider or visit the International Society for the Study of Women’s Sexual Health (ISSWSH) website for more resources.

Brooke M. Faught is a nurse practitioner and the Clinical Director of the Women’s Institute for Sexual Health (WISH), A Division of Urology Associates, in Nashville, Tennessee. She is an ISSWSH Fellow. The author states that she serves as a speaker and advisory board member for Shionogi and Valeant and an advisory board member for the Female Health Company.

**References**


**Web resource**

A. isswsh.org/